dryness, and exfoliation (Table 2). Application site irritation was reported in ≤1.2% of each race and ethnic subgroup.
Among tazarotene-treated participants who had cutaneous safety and tolerability signs and symptoms, most had mild or moderate severity at baseline and week 12 (Figure 6). Across all tazarotene-treated subgroups, there were transient increases in severity (primarily mild or moderate) at weeks 2 or 4 relative to baseline for several of the cutaneous safety and tolerability evaluations (data not shown). Investigator‑rated assessments indicated higher baseline rates (>20%) of hyperpigmentation in black participants and erythema in white, Hispanic, and non- Hispanic participants; however, all of these rates decreased by week 12. Patient‑reported tolerability assessments of itching, burning, and stinging were generally low in all subgroups, with itching tending to decrease and burning/stinging tending to increase from baseline to week 12.
